249 related articles for article (PubMed ID: 18688879)
1. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.
Tong MJ; Hsien C; Hsu L; Sun HE; Blatt LM
Hepatology; 2008 Oct; 48(4):1070-8. PubMed ID: 18688879
[TBL] [Abstract][Full Text] [Related]
2. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update.
Tong MJ; Hsu L; Chang PW; Blatt LM
J Gastroenterol Hepatol; 2011 May; 26(5):829-35. PubMed ID: 21214888
[TBL] [Abstract][Full Text] [Related]
4. A proposed, evidence-based approach to the treatment of chronic Hepatitis B.
Han SH; Durazo FA; Saab S; Tong MJ
J Clin Gastroenterol; 2011 Mar; 45(3):259-66. PubMed ID: 20856136
[TBL] [Abstract][Full Text] [Related]
5. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
[TBL] [Abstract][Full Text] [Related]
6. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
7. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.
Huo TI; Wu JC; Lee PC; Chau GY; Lui WY; Tsay SH; Ting LT; Chang FY; Lee SD
Hepatology; 1998 Jul; 28(1):231-6. PubMed ID: 9657117
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype C Chinese patients.
Zheng JX; Zeng Z; Zheng YY; Yin SJ; Zhang DY; Yu YY; Wang F
J Viral Hepat; 2011 Oct; 18(10):e423-31. PubMed ID: 21914059
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
13. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
[TBL] [Abstract][Full Text] [Related]
15. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
16. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
18. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
[TBL] [Abstract][Full Text] [Related]
19. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers.
Tong MJ; Blatt LM; Kao JH; Cheng JT; Corey WG
Liver Int; 2007 Dec; 27(10):1356-63. PubMed ID: 17900245
[TBL] [Abstract][Full Text] [Related]
20. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values.
Kumada T; Toyoda H; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Arakawa T; Fujimori M
J Med Virol; 2010 Apr; 82(4):539-45. PubMed ID: 20166172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
